• In collaboration with Max Planck Institute for Multidisciplinary Sciences (“MPI”) and the University Medical Center Göttingen, BiondVax is developing a pipeline of NanoAb therapies
• The company’s co-lead scientific research collaborator, Professor Dr. Dirk Görlich, director at MPI, was awarded the inaugural $1.4 million World Laureates Association (“WLA”) Prize in Life Sciences or Medicine for his work describing protein transport within the cell
• The global market for autoimmune disorder therapies is expected to reach $90.7 billion by 2024; The global market for infectious disease therapeutics is expected to reach $167 billion by 2030

BiondVax Pharmaceuticals (NASDAQ: BVXV) is a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious diseases and autoimmune diseases – with a primary focus on diseases underserved by current treatments and with large and growing markets, such as COVID-19, asthma, and psoriasis.

The company is developing a pipeline of innovative nanosized antibody (NanoAb) therapies in collaboration with Max Planck Institute for Multidisciplinary Sciences (“MPI”) and the University Medical Center Göttingen (“UMG”), both in Germany. The NanoAb project’s co-lead scientific research…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.